
    
      The primary objective of this study was to demonstrate the superiority of QMF149 150/80
      microgram o.d. (in the evening) delivered via Concept1 compared with MF 200 microgram o.d.
      (in the evening) delivered via TwisthalerÂ® in terms of trough FEV1 after 12 weeks of
      treatment in adults and adolescents. The key secondary objective of this study was to
      demonstrate the superiority of QMF149 150/80 microgram to MF 200 microgram o.d. in terms of
      ACQ-7 after 12 weeks of treatment.
    
  